Ionis Pharmaceuticals, Inc. Excess Tax Benefit from Share-based Compensation, Financing Activities
Ionis Pharmaceuticals, Inc. (IONS) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-01.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2019-03-01
- Ionis Pharmaceuticals, Inc. excess tax benefit from share-based compensation, financing activities for the quarter ending 2009-12-31 was $108.00K.
- Ionis Pharmaceuticals, Inc. excess tax benefit from share-based compensation, financing activities for the quarter ending 2009-09-30 was $62.00K.
- Ionis Pharmaceuticals, Inc. excess tax benefit from share-based compensation, financing activities for fiscal 2018 was $0.00.
- Ionis Pharmaceuticals, Inc. excess tax benefit from share-based compensation, financing activities for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- Ionis Pharmaceuticals, Inc. excess tax benefit from share-based compensation, financing activities for fiscal 2016 was $1.86M, a 369.95% increase from fiscal 2015.
- Ionis Pharmaceuticals, Inc. excess tax benefit from share-based compensation, financing activities for fiscal 2015 was $396.00K, a 72.93% decline from fiscal 2014.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 10-K · filed 2019-03-01 | |||
| 2017-12-31 | $0.00 10-K · filed 2019-03-01 | |||
| 2016-12-31 | $1.86M 10-K · filed 2019-03-01 | |||
| 2015-12-31 | $396.00K 10-K · filed 2018-02-28 | |||
| 2014-12-31 | $1.46M 10-K · filed 2017-03-01 | |||
| 2013-12-31 | $0.00 10-K · filed 2016-02-26 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-03-02 | |||
| 2009-12-31 | $108.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $170.00K derived: sum of 2 quarters · filed 2012-02-29 | $278.00K 10-K · filed 2012-02-29 | |
| 2009-09-30 | $62.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-05 | $170.00K 10-Q · filed 2010-11-05 | ||
| 2009-06-30 | $108.00K 10-Q · filed 2010-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |